Clinical Trials in Motherwell, United Kingdom
6 recruiting
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
Treatment Resistant Depression
atai Therapeutics, Inc.142 enrolled48 locationsNCT06524830
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled116 locationsNCT05511363
Recruiting
Phase 3
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Alzheimer Disease
Bristol-Myers Squibb352 enrolled140 locationsNCT07011745
Recruiting
Phase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled416 locationsNCT05980949
Recruiting
Phase 3
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Alzheimer DiseaseAgitation
Bristol-Myers Squibb600 enrolled241 locationsNCT06937229
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled20 locationsNCT06947941
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Memory DisordersMild Cognitive ImpairmentMemory Impairment+3 more
GAP Innovations, PBC1,200 enrolled26 locationsNCT06584357